BioCentury
ARTICLE | Clinical News

Amgen, Novartis start Phase II to prevent AD

December 1, 2017 9:51 PM UTC

In August, Novartis AG (NYSE:NVS; SIX:NOVN), Amgen Inc. (NASDAQ:AMGN) and the Banner Alzheimer’s Institute (BAI) began the Phase II Alzheimer’s Prevention Initiative (API) Generation Study 2 to evaluate CNP520 to prevent Alzheimer’s disease. The double-blind, placebo-controlled, international trial will enroll about 2,000 cognitively healthy volunteers ages 60-75 at a high risk for AD due to having at least 1 copy of the E4 allele of the apolipoprotein E (APOE) gene and elevated brain amyloid.

The companies are also conducting the Phase II Alzheimer’s Prevention Initiative (API) Generation Study 1, which is evaluating CNP520 in patients with 2 copies of the gene (see BioCentury, Sept. 12, 2016)...

BCIQ Company Profiles

Amgen Inc.

Novartis AG